Five things to watch in markets in the week ahead
Roivant Sciences Ltd. (NASDAQ:ROIV) President and Immunovant CEO Eric Venker sold 1,700,900 shares of common stock between September 19 and September 23, 2025. The sales, executed at prices ranging from $14.83 to $15.01, resulted in a total value of $25,524,777. The transactions come as the $10.1 billion market cap company’s stock trades near its 52-week high of $16.05, having surged 36% over the past six months. According to InvestingPro analysis, technical indicators suggest the stock is currently in overbought territory.
Venker also exercised options to acquire 1,562,374 common shares at a price of $3.85 per share, for a total value of $6,015,139. For deeper insights into insider trading patterns and 12+ additional exclusive tips, check out the comprehensive InvestingPro report for ROIV.
Following these transactions, Venker directly owns 1,504,959 shares of Roivant Sciences Ltd., maintaining a significant position in the company despite the recent selling activity.
In other recent news, Roivant Sciences has announced significant developments that have garnered attention from investors and analysts alike. The company reported positive results from its Phase 3 VALOR trial for brepocitinib, a treatment for dermatomyositis, showing statistically significant improvements over placebo. These results have led to an increase in price targets from major financial firms, with Goldman Sachs raising their target to $24 and H.C. Wainwright adjusting theirs to $20, both maintaining a Buy rating. The trial demonstrated that the once-daily oral medication achieved clinically meaningful outcomes, meeting both primary and secondary endpoints, including improvements in skin and muscle disease.
Additionally, TD Cowen has reiterated its Buy rating for Roivant Sciences following a favorable court ruling in a patent dispute involving Arbutus Biopharma and Pfizer/BioNTech. This court decision involved patents related to lipid nanoparticle composition and production methods, siding with Arbutus on three of four claims. These recent developments highlight the ongoing progress and challenges Roivant Sciences faces in the pharmaceutical landscape.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.